Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

FDA Takes Major Step to Save Vision
  • USA - English


News provided by

CRM Group

Mar 02, 2015, 03:00 ET

Share this article

Share toX

Share this article

Share toX


San Antonio, TX (PRWEB) March 02, 2015 -- Patients with a blinding eye disease known as Keratoconus may soon see vision-saving relief thanks to a recommendation on February 24, 2015 by the Food & Drug Administration (FDA) Panel to approve Corneal Collagen Crosslinking (CXL), said San Antonio eye surgeon, Gregory Parkhurst, MD who treated the first keratoconus patients in the United States during a corneal collagen crosslinking clinical study.¹ This treatment acts as a chemical bond to strengthen the cornea which has been weakened by keratoconus.

“As a corneal surgeon, having the ability to stop a blinding eye disease with such a gentle and proven technology is extremely gratifying, and I am thankful to the FDA Panel for making this key recommendation.” - Dr. Parkhurst

Post this

“This week’s recommendation by the FDA Panel to approve Corneal Collagen Crosslinking represents tremendous hope for thousands of patients across the country – many right here in San Antonio – who are at risk for blindness due to keratoconus and other forms of ectasia,” said Dr. Parkhurst. Keratoconus is the most common corneal dystrophy in the United States, affecting one in every 2,000 Americans, which represents over 136,000 people.

Dr. Parkhurst pointed out that there are more than 63 registered studies across the United States related to Corneal Collagen Crosslinking, including his at Parkhurst NuVision in San Antonio. “We are currently actively enrolling keratoconus patients into our FDA monitored clinical trial right here in San Antonio, and look forward to the day when we gain full FDA approval for this vision-saving procedure.”

“As a corneal surgeon, having the ability to stop a blinding eye disease with such a gentle and proven technology is extremely gratifying, and I am thankful to the FDA Panel for making this key recommendation,”he said. Dr. Parkhurst and Houston-based ophthalmologist Stephen Slade, MD were the first surgeons in the country to treat keratoconus patients as part of a national clinical trial by the American-European Congress of Ophthalmic Surgery (AECOS) and Avedro, Inc. Dr. Parkhurst has a pattern of leadership in gaining recommendations for FDA approval of modern medical technologies. Testimony from him and other experts at a similar FDA Panel last year resulted in a recommendation for approval of the Toric Implantable Contact Lens (ICL), which can help people suffering from nearsightedness and astigmatism.

Keratoconus is a degenerative eye disorder where the corneas of the eye become progressively thinner and cone-shaped, which damages vision. Common symptoms are light sensitivity, dry eyes, corneal scarring, blurred or distorted vision and the presence of myopia (nearsightedness) and astigmatism.

Corneal Collagen Crosslinking was developed in 1998 by German ophthalmologist, Theo Seiler, MD and has been shown in numerous clinical trials to strengthen the cornea using a photosensitizer (Riboflavin – a form of vitamin B-2), which is followed by a treatment with ultraviolet (UV-A) light.

Dr. Parkhurst has been actively involved in crosslinking FDA clinical trials, and also in the fields of cataract and vision correction surgery. Parkhurst NuVision, an optometrically supported integrated health care delivery system, is one of South Texas’ fastest growing LASIK and cataract centers, and was recently recognized as The First LensAR Laser Cataract Surgery Center of Excellence in the United States. Because of his total commitment to advancing treatments for his patients, and involvement in these developments, Dr. Parkhurst has been selected as the first eye surgeon in Texas to meet the criteria to serve as a Certified VisionLock surgeon. To be chosen for the VisionLock program, surgeons must meet 30 FDA, state, local and practice certification criteria and have a superior performance record. Less than 5% of eye surgeons nationwide meet VisionLock requirements and provide patients this visual results outcomes insurance coverage free of charge.

“Having expanded access to Crosslinking, an outpatient procedure that prevents me from having to do a major corneal transplant surgery, is a huge leap forward for all of my patients with keratoconus,” Dr. Parkhurst said.

For additional information about this press release, please visit http://www.sanantonio-lasik.com or contact Jesse Montoya at 210-615-9358.

1: American Society of Ophthalmic Administrators, February 25, 2015; http://www.asoa.org/news/joint-panel-recommends-fda-approval-drug-device-combination-cxl-progressive-keratoncus-and

###

Michael Malley, CRM Group, http://www.refractivemarketing.com, +1 281-583-7542, [email protected]

Modal title

Eye Surgeon Gregory Parkhurst, MD
Eye Surgeon Gregory Parkhurst, MD
Eye Surgeon Gregory Parkhurst, MD

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.